RLY-5836 + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
PIK3CA Mutation
Conditions
PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
Trial Timeline
Mar 29, 2023 → Apr 11, 2025
NCT ID
NCT05759949About RLY-5836 + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib
RLY-5836 + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib is a phase 1 stage product being developed by Relay Therapeutics for PIK3CA Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT05759949. Target conditions include PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05759949 | Phase 1 | Completed |
Competing Products
13 competing products in PIK3CA Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Miransertib | Merck | Phase 2 | 52 |
| Miransertib | Merck | Phase 1/2 | 41 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib | Novartis | Phase 2 | 52 |
| Alpelisib + Placebo | Novartis | Phase 2 | 52 |
| alpelisib | Novartis | Pre-clinical | 23 |
| BYL719 + Fulvestrant | Novartis | Phase 1 | 33 |
| BYL719 + AMG 479 | Novartis | Phase 1/2 | 41 |
| Inavolisib + Atezolizumab + Pembrolizumab | Roche | Phase 1 | 33 |
| CGT6297 | Cogent Biosciences | Phase 1 | 30 |
| RLY-2608 + Placebo | Relay Therapeutics | Phase 2 | 47 |
| RLY-2608 + Capivasertib + Fulvestrant | Relay Therapeutics | Phase 3 | 72 |
| RLY-2608 + Fulvestrant + Palbociclib 125mg + Ribociclib 400mg + Ribociclib 600mg + PF-07220060 100mg + PF-07220060 300 mg | Relay Therapeutics | Phase 1 | 28 |